Staging non—small cell lung cancer by whole-body positron emission tomographic imaging

Valk, Peter E.; Pounds, Thomas R.; Hopkins, Donald M.; Haseman, Michael K.; G, Hofer; Greiss, Hani B.; Myers, Richard; Lutrin, Calvin

doi:10.1016/0003-4975(95)00752-0

Cited by 297 publications

(120 citation statements)

References 17 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…Valk et al [117], in a recently reported study concerning subsets of 76 and 99 patients, also noted that PET correctly changed the nodal stage as determined by CT in 18 staging evaluations (24%), increasing the stage in eight patients and decreasing it in 11, including one false-negative. PET changed the metastasis stage in 30 patients: previously unsuspected distant metastases were demonstrated in 11 patients while normal PET findings were obtained at distant sites of CT abnormalities in 19 patients (one false-negative).…”

Section: Fig 2 Malignant Solitary Pulmonary Nodule (Adenosquamous Cmentioning

confidence: 86%

“…These studies must be separated into two groups, Some investigators have used focal techniques and have concentrated on hilar and mediastinal lymph node staging, while others have used whole-body techniques and have evaluated extrathoracic (Table 2) [49,[110][111][112][113][114][115][116][117][118][119]. The reported sensitivity for lymph node staging in non-small cell lung cancer varies from 82% to 100% and the specificity from 73% to 100%.…”

Section: Fig 2 Malignant Solitary Pulmonary Nodule (Adenosquamous Cmentioning

confidence: 99%

See 1 more Smart Citation

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

Abstract. Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and followup. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.

show abstract

Section: Fig 2 Malignant Solitary Pulmonary Nodule (Adenosquamous Cmentioning

confidence: 86%

Section: Fig 2 Malignant Solitary Pulmonary Nodule (Adenosquamous Cmentioning

confidence: 99%

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

show abstract

“…PET has been shown to correctly increase or decrease nodal staging as initially determined by CT in 21% of presurgical patients [66]. In a study of 50 patients where PET and CT findings were reported jointly, the sensitivity rose to 93%, specificity 97% and accuracy 96% in the detection of mediastinal nodal disease [63].…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Diagnostic imaging of lung cancer

Hollings¹,

Shaw²

2002

Eur Respir J

124

View full text Add to dashboard Cite

Carcinoma of the bronchus is the most common malignancy in the Western world. It is also the leading cause of cancer-related death accounting for 32% of all cancer deaths in males and 25% in females [1]. In the USA it causes more deaths than cancers of the colon, breast and prostate combined [2]. Disappointingly, in a recent UK survey of improvements in cancer survival [3], carcinoma of the bronchus showed the smallest percentage reduction in the number of deaths avoided between 1981-1990 (0.2%). This compares badly with breast (11% reduction) and melanoma (32%). The overall 5-yr survival for lung cancer diagnosed between 1986-1990 was only 5.3% (against 66% for breast and 76% for melanoma). It is on this background that the radiologist remains actively employed in the detection, diagnosis, staging and review of this common malignancy.

show abstract

“…Animal experiments with human gastric cancer xenografts also showed that FDG uptake is correlated with the differentiation of the tumour (Yoshioka et al, 1994). PET has already established a role in the staging of other tumours such as lung cancer and colon cancer (Valk et al, 1995;Vitola et al, 1996;Delbeke et al, 1997;Guhlmann et al, 1997;Steinert et al, 1997). The current study was undertaken to investigate FDG-PET prospectively as a means of detecting metastatic disease in patients with oesophageal tumours and of comparing the reliability of diagnostic assessment of PET with CT, with the surgical and histological findings as a gold standard.…”

mentioning

confidence: 97%

Positron emission tomography for staging of oesophageal and gastroesophageal malignancy

Kole

Plukker²,

Nieweg³

et al. 1998

Br J Cancer

166

View full text Add to dashboard Cite

Summary Positron emission tomography (PET) with [18F]-fluoro-2-deoXy-D-glucose (FDG) was prospectively investigated as a means of detecting metastatic disease in patients with oesophageal tumours and compared with computerized tomography (CT), with the surgical findings as a gold standard. Twenty-six patients with a malignant tumour of the oesophagus or gastroesophageal junction underwent CT and PET of the chest and the abdomen. Seven patients underwent laparoscopy to establish resectability. Fifteen patients underwent laparotomy without prior laparoscopy. Four patients did not undergo surgery. The primary tumour was visualized in 81% of patients with CT and in 96% with PET. Neither CT nor PET were suited to assess the extent of wall invasion. Surgically assessed nodal status corresponded in 62% with CT and in 90% with PET. Distant metastases were found in five patients with CT and in eight with PET. The diagnostic accuracy of CT in determining resectability was 65% and for PET 88%. For CT and PET together this was 92%. The present study indicates that FDG-PET can be of importance for staging patients with oesophageal tumours. PET has a higher sensitivity for nodal and distant metastases and a higher accuracy for determining respectability than CT. PET and CT together would have decreased ill-advised surgery by 90%.

show abstract

Staging non—small cell lung cancer by whole-body positron emission tomographic imaging

Cited by 297 publications

References 17 publications

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Diagnostic imaging of lung cancer

Positron emission tomography for staging of oesophageal and gastroesophageal malignancy

Contact Info

Product

Resources

About